Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 18/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19092109 | 0.91 | CACNA1H (0.55) | CACNA1HKCNH2CACNA1I | |
| SCHEMBL19082642 | 0.88 | CACNA1H (0.65) | CACNA1H | |
| SCHEMBL4278224 | 0.80 | CACNA1I (0.60) | CACNA1HKCNH2CACNA1IOPRL1 | |
| SCHEMBL19082615 | 0.79 | CACNA1H (0.68) | CACNA1H | |
| SCHEMBL4271317 | 0.73 | CACNA1I (0.60) | CACNA1HKCNH2CACNA1I | |
| SCHEMBL20725563 | 0.73 | SMN1; SMN2 (0.48) | CACNA1HKCNH2CACNA1IOPRL1 | |
| SCHEMBL22018882 | 0.71 | CACNA1I (0.51) | CACNA1HKCNH2CACNA1I | |
| SCHEMBL26082220 | 0.71 | CACNA1I (0.74) | CACNA1HKCNH2CACNA1IOPRL1 | |
| SCHEMBL19082624 | 0.68 | CACNA1H (1.00) | CACNA1H | |
| SCHEMBL26082223 | 0.67 | CACNA1I (0.68) | CACNA1HKCNH2CACNA1IOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190699-A1 | SUBSTITUTED TROPANE DERIVATIVES | TOA EIYO LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190699-A1 | SUBSTITUTED TROPANE DERIVATIVES | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885KCNH2 68/4885CACNA1I 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.